Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Fetal gene therapy for neurodegenerative disease of infants.

Massaro G, Mattar CNZ, Wong AMS, Sirka E, Buckley SMK, Herbert BR, Karlsson S, Perocheau DP, Burke D, Heales S, Richard-Londt A, Brandner S, Huebecker M, Priestman DA, Platt FM, Mills K, Biswas A, Cooper JD, Chan JKY, Cheng SH, Waddington SN, Rahim AA.

Nat Med. 2018 Sep;24(9):1317-1323. doi: 10.1038/s41591-018-0106-7. Epub 2018 Jul 16.

2.

Improving Fab' fragment retention in an autonucleolytic Escherichia coli strain by swapping periplasmic nuclease translocation signal from OmpA to DsbA.

Schofield DM, Sirka E, Keshavarz-Moore E, Ward JM, Nesbeth DN.

Biotechnol Lett. 2017 Dec;39(12):1865-1873. doi: 10.1007/s10529-017-2425-z. Epub 2017 Sep 5.

3.

A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin.

Kinghorn KJ, Grönke S, Castillo-Quan JI, Woodling NS, Li L, Sirka E, Gegg M, Mills K, Hardy J, Bjedov I, Partridge L.

J Neurosci. 2016 Nov 16;36(46):11654-11670.

4.

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.

Paterson RW, Heywood WE, Heslegrave AJ, Magdalinou NK, Andreasson U, Sirka E, Bliss E, Slattery CF, Toombs J, Svensson J, Johansson P, Fox NC, Zetterberg H, Mills K, Schott JM.

Transl Psychiatry. 2016 Nov 15;6(11):e952. doi: 10.1038/tp.2016.194.

5.

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status.

Heywood WE, Baud A, Bliss E, Sirka E, Schott JM, Zetterberg H, Galimberti D, Sebire NJ, Mills K.

J Vis Exp. 2016 Oct 20;(116). doi: 10.3791/54541.

6.

Erratum to: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia KP, Heales S, Sebire NJ, Zetterberg H, Mills K.

Mol Neurodegener. 2016 Feb 23;11:20. doi: 10.1186/s13024-016-0086-3. No abstract available.

7.

Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.

Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK, Carecchio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox NC, Hardy J, Bhatia K, Heales S, Sebire NJ, Zetterberg H, Mills K.

Mol Neurodegener. 2015 Dec 1;10:64. doi: 10.1186/s13024-015-0059-y. Erratum in: Mol Neurodegener. 2016;11:20. Bahtia, Kailash and Zetterburg, Henrik [Corrected to Bhatia, Kailash and Zetterberg, Henrik].

Supplemental Content

Support Center